Bulevirtide for chronic hepatitis delta
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic hepatitis delta (a type of hepatitis D that lasts a long time)
- You have cirrhosis (scarring of the liver) that is still working well (compensated)
- You are planning to start Bulevirtide 2 mg daily starting May 2023
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
Hear when a new Hepatitis D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.